With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

2.

Mezigdomide Combinations Show Promise in Multiple Myeloma

3.

Did U.S. Government Play a Role in Remote Tribe's Widespread Illness and Cancer?

4.

Prostate cancer explained: From antigen tests to treatment options

5.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot